225 related articles for article (PubMed ID: 32507512)
1. Successful management of eosinophilic chronic rhinosinusitis complicated by severe asthma using dupilumab, following negative initial results with benralizumab.
Suzaki I; Tanaka A; Hirano K; Arai S; Kobayashi H
Allergol Int; 2021 Jan; 70(1):150-152. PubMed ID: 32507512
[No Abstract] [Full Text] [Related]
2. Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma.
Tajiri T; Matsumoto H; Hiraumi H; Ikeda H; Morita K; Izuhara K; Ono J; Ohta S; Ito I; Oguma T; Nakaji H; Inoue H; Iwata T; Nagasaki T; Kanemitsu Y; Ito J; Niimi A; Mishima M
Ann Allergy Asthma Immunol; 2013 May; 110(5):387-8. PubMed ID: 23622013
[No Abstract] [Full Text] [Related]
3. Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma.
Lombardo N; Pelaia C; Ciriolo M; Della Corte M; Piazzetta G; Lobello N; Viola P; Pelaia G
Int J Immunopathol Pharmacol; 2020; 34():2058738420950851. PubMed ID: 32816558
[TBL] [Abstract][Full Text] [Related]
4. Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double-blind placebo-controlled trial.
Tversky J; Lane AP; Azar A
Clin Exp Allergy; 2021 Jun; 51(6):836-844. PubMed ID: 33595845
[TBL] [Abstract][Full Text] [Related]
5. Cycling therapy with benralizumab and dupilumab for severe eosinophilic asthma with eosinophilic chronic rhinosinusitis and eosinophilic otitis media.
Hamada S; Ogino E; Yasuba H
Allergol Int; 2021 Jul; 70(3):389-391. PubMed ID: 33685801
[No Abstract] [Full Text] [Related]
6. Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
Weinstein SF; Katial RK; Bardin P; Korn S; McDonald M; Garin M; Bateman ED; Hoyte FCL; Germinaro M
J Allergy Clin Immunol Pract; 2019 Feb; 7(2):589-596.e3. PubMed ID: 30193936
[TBL] [Abstract][Full Text] [Related]
7. Benralizumab strongly reduces blood basophils in severe eosinophilic asthma.
Lommatzsch M; Marchewski H; Schwefel G; Stoll P; Virchow JC; Bratke K
Clin Exp Allergy; 2020 Nov; 50(11):1267-1269. PubMed ID: 32762056
[No Abstract] [Full Text] [Related]
8. Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis.
Numata T; Nakayama K; Utsumi H; Kobayashi K; Yanagisawa H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
BMC Pulm Med; 2019 Oct; 19(1):176. PubMed ID: 31606052
[TBL] [Abstract][Full Text] [Related]
9. IL13 May Play an Important Role in Developing Eosinophilic Chronic Rhinosinusitis and Eosinophilic Otitis Media with Severe Asthma.
Shimizu H; Hayashi M; Kato H; Nakagawa M; Imaizumi K; Okazawa M
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681869
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials.
Tian BP; Zhang GS; Lou J; Zhou HB; Cui W
J Asthma; 2018 Sep; 55(9):956-965. PubMed ID: 29211545
[TBL] [Abstract][Full Text] [Related]
11. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
[TBL] [Abstract][Full Text] [Related]
12. HFA-BDP Metered-Dose Inhaler Exhaled Through the Nose Improves Eosinophilic Chronic Rhinosinusitis With Bronchial Asthma: A Blinded, Placebo-Controlled Study.
Kobayashi Y; Yasuba H; Asako M; Yamamoto T; Takano H; Tomoda K; Kanda A; Iwai H
Front Immunol; 2018; 9():2192. PubMed ID: 30337921
[No Abstract] [Full Text] [Related]
13. Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis.
Tsurumaki H; Matsuyama T; Ezawa K; Koga Y; Yatomi M; Aoki-Saito H; Chikamatsu K; Hisada T
Medicina (Kaunas); 2019 Jul; 55(7):. PubMed ID: 31277327
[TBL] [Abstract][Full Text] [Related]
14. Benralizumab in Real Life.
Miralles López JC; Escudero Pastor AI; Carbonell Martínez A; Navarro Garrido C; Bonilla Pacheco Y; Petrik Petrik Y
J Investig Allergol Clin Immunol; 2021 Feb; 31(1):87-88. PubMed ID: 32573458
[No Abstract] [Full Text] [Related]
15. Reslizumab (Cinqair) for severe eosinophilic asthma.
Med Lett Drugs Ther; 2016 Jun; 58(1497):81-2. PubMed ID: 27305070
[No Abstract] [Full Text] [Related]
16. Last station in the eosinophilic asthma with chronic rhinosinusitis and/or nasal polyposis march: Eosinophilic asthma with radiological findings associated with blood eosinophilia.
Yılmaz I; Bahçecioğlu SN; Türk M; Tutar N; Oymak FS; Gülmez İ
J Asthma; 2019 Feb; 56(2):111-117. PubMed ID: 29611776
[TBL] [Abstract][Full Text] [Related]
17. Controversies in Allergy: Should Severe Asthma with Eosinophilic Phenotype Always Be Treated with Anti-IL-5 Therapies.
Pavord ID; Hanania NA
J Allergy Clin Immunol Pract; 2019; 7(5):1430-1436. PubMed ID: 30962155
[No Abstract] [Full Text] [Related]
18. Dupilumab therapy for patients with refractory eosinophilic otitis media associated with bronchial asthma.
Iino Y; Sekine Y; Yoshida S; Kikuchi S
Auris Nasus Larynx; 2021 Jun; 48(3):353-360. PubMed ID: 32943257
[TBL] [Abstract][Full Text] [Related]
19. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis.
Nagase H; Ueki S; Fujieda S
Allergol Int; 2020 Apr; 69(2):178-186. PubMed ID: 32139163
[TBL] [Abstract][Full Text] [Related]
20. Early decreases in blood eosinophil levels with reslizumab.
Chanez P; McDonald M; Garin M; Murphy K
J Allergy Clin Immunol; 2019 Apr; 143(4):1653-1655. PubMed ID: 30654046
[No Abstract] [Full Text] [Related]
[Next] [New Search]